Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Alder Biopharmaceuticals Inc.
Headquarters: Bothell, WA, United States of America
Website: N/A
Year Founded: 2004
Status: Acquired
BioCentury | Mar 17, 2025
Product Development
Lundbeck’s next chapter: from psychiatry to rare neuro
Leaving past limitations behind, Danish pharma widens its technology aperture to brain shuttles, AI and more
BioCentury | Oct 14, 2024
Deals
Lundbeck bolts on Longboard, gains anticonvulsive in $2.6B deal
Danish pharma eyeing growth beyond loss of exclusivity for Rexulti, aiming for broad label in rare epilepsies
BioCentury | Jan 5, 2023
Management Tracks
Sanofi’s Sarchi heads to Replimune
Plus: Albers joins Atlas, new CBO at Altimmune and updates from Nuvig, Zymeworks, Fulcrum, Step, Charm, Kymera and more
BioCentury | Oct 18, 2022
Product Development
Lundbeck pivot emphasizes first in class in revamped pipeline
Dunsire era brings new blood to R&D, appetite for risk, and open doors for partnering
BioCentury | Jan 29, 2021
Management Tracks
KoreaBIO picks Samsung Bioepis’ Ko as presient; plus Adaptive, Omeros, Acadia, ViaCyte, Flexion, Aquestive, GreenLight
Korea Biotechnology Industry Organization appointed Christopher Hansung Ko as the new president of the trade group. Ko is the CEO of biosimilars company Samsung Bioepis Co. Ltd. Immune medicine
BioCentury | Dec 3, 2020
Management Tracks
Management Tracks: Zai taps Sandler as cancer head, plus moves at FibroGen, Arena, Samumed, Avita, Mersana, Frequency, Matinas, NeuBase, Allena and RA
Zai Lab Ltd. (NASDAQ:ZLAB; HKEX:9688) hired Alan Sandler as president, head of global development, oncology, a newly created position. Sandler was SVP and global head of product development oncology
BioCentury | Sep 12, 2020
Management Tracks
New CEO Hirsch to guide C4 onto NASDAQ; plus Biller adds CFO title at Agios and updates from Sherlock, Lumen and more
It’s been a busy week for C4 Therapeutics Inc., which hired a new CEO and filed to go public. Andrew Hirsch is joining the protein degradation company from Agios
BioCentury | Mar 28, 2020
Management Tracks
Bernard joins Qiagen as CEO; plus CytomX, Recursion, 89bio, Heptares, Fusion, Freeline, Cognition, I-Mab, Seres and more
BioCentury | Feb 22, 2020
Product Development
FDA approves Lundbeck's Vyepti, the first CGRP inhibitor for migraine delivered IV
With little difference in efficacy or price, the CGRP competition will boil down to delivery, frequency and access
BioCentury | Jan 11, 2020
Finance
Why buysiders say 2020 could be the year of the CNS
Neurology is back, as buysiders home in on 2020 opportunities
Items per page:
1 - 10 of 144